Siblings 圖書 [5/7] 期刊論文 [159/159] Collection Statistics 近3年內發表的文件:4(12.50%) 含全文筆數:25(78.12%) 文件下載次數統計 下載大於0次:25(100.00%) 下載大於100次:22(88.00%) 檔案下載總次數:13457(14.10%) 最後更新時間: 2024-12-03 01:46 Top Upload Loading... Top Download Loading... Recent Submissions The registry of genetic alterations... Nivolumab plus ipilimumab (N plus I... BEAR study: A single-arm, phase II ... A phase II trial of nivolumab, gemc... A phase 2 study of liposomal irinot... TCOG T5217 trial: A phase II random... A phase II trial of nivolumab and g... An open label, single-arm, two-stag... Interaction of smoking and hOGG1 Se... Assessing benefit and consistency o...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1-10 of 32. (4 Page(s) Totally) 1 2 3 4 > >> View [10|25|50] records per page

Date	Title	Relation
2023-11	Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome	Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
2023-11	The registry of genetic alterations of Taiwan NSCLC by comprehensive next-generation sequencing: A real-world cohort study - TCOG T1521 study	Journal of Thoracic Oncology. 2023 Nov;18(11, Suppl.):S52.
2022-11	BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma	Annals of Oncology. 2022 Nov;33(Suppl. 9):S1472-S1473.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.
2021-05	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143.
2021-05	A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025.
2019-05	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14)	Journal of Clinical Oncology. 2019 May;37(15, Suppl. S):Abstract number 4101.
2017-05	Efficient group-sequential designs for monitoring two time-to-event outcomes in clinical trials	Trials. 2017 May;18(Suppl. 1):Meeting Abstract P36.
2016-11-11	Assessing benefit and consistency of treatment effect under a discrete random effects model in multiregional clinical trials	Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. 2016 Nov 11:127-136.

Showing items 1-10 of 32. (4 Page(s) Totally) 1 2 3 4 > >> View [10|25|50] records per page